Locations
San Diego, CA, USA · North America · Liberty Station, San Diego, CA, USA
industry
Biotechnology
Size
11 - 50 employees
Stage
Series B
founded in
2018
Gallant is an animal health biotechnology company pioneering "ready-to-use" stem cell therapies for pets. Gallant's pipeline of off-the-shelf mesenchymal stem cell (MSC) therapies addresses conditions in dogs and cats—including Feline Chronic Gingivostomatitis (FCGS), osteoarthritis, chronic kidney disease, and atopic dermatitis. Our first product, based on a proprietary uterine-derived stem cell platform, is on track for conditional FDA approval in 2026. Led by industry pioneers in veterinary regenerative medicine, Gallant combines science, purpose, and compassion to help pets live healthier, more vibrant lives.
Something looks off?